Controversies and strengths in prophylactic total gastrectomy for germline CDH1 pathogenic variant carriers.

Abstract

aCenter for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland bGastric and Mixed Tumor Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA Received 15 March 2023 Accepted 15 March 2023. *Vivian E. Strong equally contributed to this article. Correspondence to Jeremy L. Davis, MD, 10 Center Drive, Rm 4-3742, Bethesda, MD 20892, USA Tel: +1 240 858 3731; e-mail: [email protected]